Chinese Spondyloarthritis Inception Cohort (CESPIC)
Observational · No treatment assigned · Sites not listed yet · Southwest Hospital, China
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA) and Axial Psoriatic Arthritis (axPsA). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Age range not stated in the record
- Any sex
Some of the main requirements, copied from the record:
- Crohn's disease. Acute anterior uveitis. Psoriatic arthritis with axial involvement. Reactive arthritis.
There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 1000 participants are expected to take part.
- Start date: 2024-09 (planned).
- Main results expected around 2025-08 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- BASDAI (baseline)
In the researchers’ words
The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately…
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA); Non-radiographic Axial Spondyloarthritis (Nr-axSpA); Axial Psoriatic Arthritis (axPsA); Acute Anterior Uveitis (AAU); Crohn Disease (CD); Ulcerative Colitis (UC); Reactive Arthritis (ReA) |
| Lead sponsor | Southwest Hospital, China |
| Enrollment | 1000 (estimated) |
| Start date | 2024-09 |
| Primary completion (est.) | 2025-08 |
| First posted | 2023-07-27 |
| Last updated | 2024-04-17 |
| Official title | Chinese Spondyloarthritis Inception Cohort |
| ClinicalTrials.gov ID | NCT05960864 |
Interventions
- Celecoxib (Drug)
If we find any behavior that affects the safety of patients in the experiment, we will stop
Full eligibility criteria (from the record)
Inclusion Criteria: Crohn's disease. Acute anterior uveitis. Psoriatic arthritis with axial involvement. Reactive arthritis. Exclusion Criteria: Infections, Malignancies, Major cardiovascular events, Lower intestinal perforations Other adverse events
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.